Ligand Pharmaceuticals Inc Insider Trading
Every director, officer and 10% holder of Ligand Pharmaceuticals Inc has to report each trade in its stock within two business days of making it. This is those filings.
LGND on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Andrew ReardonCLO & Secretary2026-10-02833 shat $302.51 | Sale10b5-1 plan | $252K |
| Andrew ReardonCLO & Secretary2026-10-022K shat $303.54 | Sale10b5-1 plan | $599.8K |
| Andrew ReardonCLO & Secretary2026-10-021.5K shat $304.52 | Sale10b5-1 plan | $467.4K |
| Andrew ReardonCLO & Secretary2026-10-02404 shat $306.18 | Sale10b5-1 plan | $123.7K |
| Andrew ReardonCLO & Secretary2026-10-02235 shat $307.19 | Sale10b5-1 plan | $72.2K |
| Andrew ReardonCLO & Secretary2026-10-0217 shat $307.74 | Sale10b5-1 plan | $5.2K |
| Martine ZimmermannDirector2026-09-101.2K shat $285.00 | Sale | $342K |
| Andrew ReardonCLO & Secretary2026-09-03300 shat $283.99 | Sale10b5-1 plan | $85.2K |
| Andrew ReardonCLO & Secretary2026-09-031.8K shat $285.17 | Sale10b5-1 plan | $513.3K |
| Andrew ReardonCLO & Secretary2026-09-032.1K shat $286.36 | Sale10b5-1 plan | $605.6K |
| Andrew ReardonCLO & Secretary2026-09-03385 shat $287.53 | Sale10b5-1 plan | $110.7K |
| Andrew ReardonCLO & Secretary2026-09-03400 shat $288.98 | Sale10b5-1 plan | $115.6K |
| Octavio EspinozaChief Financial Officer2026-08-1231.6K shat $292.07 | Sale10b5-1 plan | $9.2M |
| Jason HaasDirector2026-08-127.1K shat $292.81 | Sale | $2.1M |
| Andrew ReardonCLO & Secretary2026-08-03105 shat $284.14 | Sale10b5-1 plan | $29.8K |
| Andrew ReardonCLO & Secretary2026-08-0333 shat $284.55 | Sale10b5-1 plan | $9.4K |
| Andrew ReardonCLO & Secretary2026-08-03157 shat $285.74 | Sale10b5-1 plan | $44.9K |
| Andrew ReardonCLO & Secretary2026-08-031K shat $286.80 | Sale10b5-1 plan | $296K |
| Andrew ReardonCLO & Secretary2026-08-031.2K shat $287.77 | Sale10b5-1 plan | $349.4K |
| Andrew ReardonCLO & Secretary2026-08-03356 shat $288.75 | Sale10b5-1 plan | $102.8K |
| Andrew ReardonCLO & Secretary2026-08-03503 shat $289.80 | Sale10b5-1 plan | $145.8K |
| Andrew ReardonCLO & Secretary2026-08-03200 shat $290.60 | Sale10b5-1 plan | $58.1K |
| Andrew ReardonCLO & Secretary2026-08-03991 shat $291.71 | Sale10b5-1 plan | $289.1K |
| Andrew ReardonCLO & Secretary2026-08-03409 shat $292.82 | Sale10b5-1 plan | $119.8K |
| Andrew ReardonCLO & Secretary2026-07-01396 shat $308.99 | Sale10b5-1 plan | $122.4K |
| Andrew ReardonCLO & Secretary2026-07-01104 shat $310.20 | Sale10b5-1 plan | $32.3K |
| Andrew ReardonCLO & Secretary2026-07-011.1K shat $311.72 | Sale10b5-1 plan | $348.8K |
| Andrew ReardonCLO & Secretary2026-07-011.1K shat $312.28 | Sale10b5-1 plan | $337.6K |
| Andrew ReardonCLO & Secretary2026-07-01700 shat $313.46 | Sale10b5-1 plan | $219.4K |
| Andrew ReardonCLO & Secretary2026-07-01100 shat $314.58 | Sale10b5-1 plan | $31.5K |
| Andrew ReardonCLO & Secretary2026-07-01900 shat $315.78 | Sale10b5-1 plan | $284.2K |
| Andrew ReardonCLO & Secretary2026-07-01600 shat $317.15 | Sale10b5-1 plan | $190.3K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on LGND
Follow Ligand Pharmaceuticals Inc (LGND) by email
New trades in Ligand Pharmaceuticals Inc (LGND) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.